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Objrcbives, This study examined perloperedve and intermedi-
ate outcomes in pediatric cardiac transplant recipients who had
elevated pulmonary vascular resistance Indexes preoprrMhdy.
Background, Elevated pulmonary vascular resistance, wen us-
soelated with poor enlrmle in previous studies and constitutes a
ruhatiTe conlraindkalton to transplantation. Few studio bare
evaluated this pow omeoene risk factor In pediatric patients .
Me%hadr. To evaluate ooRanes d rrururecudd transplant reelp-
fts, records were reviewed end divided into Group I (preoperative
pldroamy vascular resistance bodes w6 uahs•mt) and Group 11
(pubamary vascular resistance idea <6 wats•m2). Dmw/redpieet
weight ribs, lchemic dmn, knob of iataslve ewe unit my,
pomr-gdaldMn hdexdon rates, arrhydmda, response to pre •
h :mphmatbe vasodaator idmlons and pohmnary vascular emie-
tanreindexesattheRest andmwtreeeot posdartamplamholoa bleptm
were analyzed .
Results. Group 1 (8 patterns) had a mean (±SEM) paloouary
vascular resistance index
of
11 .5 t 3.5 urdts •mt
; Group 11 (29
patiKS) had a mesa pulamwy vascular resistance Index of 2 .3 *
0A units m' (p < 0.002). Pulmonary vascular resistance idol
decreased from 12.3 t 3.9 to 3.9 x0.9 unllsm t (p < 0.05) In 7
Elevated pulmonary vascular resistance has been associated
with increased perioperative morbidity and mortality in
cardiac transplant recipients (1-4) . Because of high right-
sided afterload and veer riculnr failure in an unprepared
dchor heart, many centers consider patients with high pul-
monary vascular resistance unacceptable transplantation
candidates . Those centers that are willing to accept trans-
plantation patients with high pulmonary vascular resistance,
while reporting no pulmonary vascular resistance above
which transplantation is ebsolutely contraindicated, have
suggested that the use of significantly oversized donors from
local referral bases (short ischemic times) will maximize
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Group I patients undergoing vasedlialor loll lash during pre4ans .
piamatton W6eterladm, Thirty-sin arlhotapic heart V-
0-den; were performed and one hNaveapk waspt7111att m, Dow
weights exceeded eecplam weights by 13% and 31% for Groups I
jest
II, reapeeltvely (p > 015) . Dams iarkemie fimewas215 mho foe
Group l std 225 ads firGreap B (p> 0.75). htemivecme
NOR
my
was 11 .5 days i Grasp I and 15.1 days h1 Group B (p = "I,
Ideedon rate am 38% i both grumps Ip > 0 .001. Arrblrdm
occurred i 90% of
Grasp I and 42% of Grasp D (p < OM)
patients. Pulmonary resistance ides In Group I decreased from
11 .5 t 3.5 to 3.7 S 1 .2 ook•m a (p < 0.03) by ft AM
pastrami
biopsy and love aol changed mbsquendy .
brig 2.3yan (tongs O.3 to &$)of fabw-ap, then : mortdhy rah
was 25% and 21% for Groups I and II, reepectivdy (p > 0 .00).
Coachman .
Group I patients did rd rqulre
s411111-ally
eventual donors, reshickd donor locations or heger Intensive
are mat stays or base higher Infection raft; however, wAyb-
miss were more frequent
. Fdau may reddaa index awambed
early alter eons pIanWMu. poMrouary vmeulw radHRy may be
more Important for survival than absolute rvdotaoce hdes,
(J Am Can Cordial 1994;23:1402-7)
postoperative survival (1-3) . Much of these data me derived
from studies of
adult recipients, however, and few pediatric
patients have been described. In those sulks of pediatric
recipients (4), the major emphasis has focused on efforts to
optimize immediate postoperative survival, but few studies
document intermediate and long-term results or address the
natural history of pulmonary hypertension and elevated pul-
monary vascular resistance alter transplantation . This report
describes our intermediate outcomes in patients with elevated
pulmonary vascular resistance with particular attention to
donor characteristics, postoperative complications, changes in
pulmonary vascular resistance after transplataion and the
feasibility of pediatric cardiac tmnsplamation in patients with
pulmonary vascular resistance indexes >6 unils •m2,
Methods
Records of 37 pediatric transplant recipients why under-
went cardiac transplantation between 1904 and 1992 were
reviewed and assigned to two groups . Neonatal patients who
0775-1e971Yo3710a
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Table I.
Pretransplantation Diagnoses and Hemodynamic Data for Group I
DCM = dilated cardiomyopathy :
F = female
: M = mate ; PAP = pulmum+ry artery pressure;
PAWP = pulmonary
artery wedge pressure; Pt = patient ; PVRI = pulmonary vascular resistance index ; Ti = transplantation.
underwent transplantation for hypoplastic left heart syn-
drome and did not have catheterization data available to
calculate pulmonary vascular resistance index, conse-
quently, were excluded from the analysis . Group I included
patients whose pretransplantation pulmonary vascular resis-
tance index was a6 units-m
2 ,
and Group It patients had a
pulmonary vascular resistance index <6 units-m2
. In addi-
tion to pretransplantation pulmonary vascular resistance
index values, changes in pulmonary vascular resistance
index using vasodilator agents during pretransplantation
catheterization were recorded in Group I patients . In this
study, the vasodilator protocol consisted of supplemental
oxygen followed by incrementally increasing infusion con-
centrations of prostaglandin E I from 0 .05 to 0.1 Ag/kg body
weight per min with an end point of lowest e:sistance or
systemic hypotension
. Donor/recipient weight ratios, post
transplantation infection rates (number of culture positive
episodes in the first posttransplantation month regardless of
etiologic organism), total ischernic time, length of intensive
care unlit stay and survival data were collected for each
patient. Sustained and nonsustained atria] or ventricular
arrhythmias (excluding single premature atrial or ventricular
contractions), identified by electrocardiogram, telemetry or
Holler monitor occurring within the first week after trans-
plantation were considered perioperative arrhythmias and
were recorded for analysis. Serial pulmonary vascular resis-
tance indexes were measured, as described earlier, as part of
the routine posttransplantation catheterization and endo-
myocardial biopsy performed for rejection surveillance . Val-
ues from the first posttransplantation catheterization (usual-
ly performed 10 days postoperatively) and the most recent
(0 .3 to 6.5 years of follow-up)
were obtained for statistical
comparison with preoperative measurements to determine
the natural history of elevated pulmonary vascular resis-
tance in children .
Statistical methods. Statistical analyses included para-
metric and nonparamettic comparisons of continuous and
categoric variables, respectively
. In cases where the equal
variance assumption of parametric methods (Students r and
paired t tests) was violated, nonparametric analogs
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(Wilcoxon rank sum test or Mann-Whitney U test) were
utilized. Numerical results are expressed as mean values ±
SEM and became statistically significant at p < 0 .05 . Actu-
arial survival curves were calculated using the Kaplan-Meier
method and are shown with 95% Greenwood confidence
intervals .
Results
Preoperative hemodynamic variables . Pretransplantation
diagnoses and hemodynamic data for Groups I and 11 are
presented in Tables I and 2, respectively. Group I included
8 patients with a mean pulmonary vascular resistance index
of 11 .5 ± 3 .5 units-m2, and Group II included 29 patients
with a mean pulmonary vascular resistance index of 2 .3 t
0 .4 units-m2 (p < 0.002). Seven Group I patients underwent
vasodilator agent infusion protocols during pretransplanta-
tion catheterization with a mean pulmonary vascular resis-
tance index decrease from 12.3 ± 3 .9 to 3.9 ± 0.9
units-m2
(p < 0.05) (Table I, Fig . 1).
Perloperative data. Orlhntopic transplantation was per-
formed in 35, of 31 patients . Patient 8 in Group I had
a measured pulmonary vascular resistance index of
36 umts-m 2 preoperatively, which decreased to 8 units-rat
with vasodilator agent therapy and was considered at high
risk for orthotopic transplantation . He subsequently under-
went successful heterotopic transplantation. The early mor-
tality rate was 12% (1 of 8 patients) in Group I and 4% (1 of
29 rvtients) in Group I[ (p = 0.99)
. Eighty percent of donor
weights were recorded at the time of transplantation, includ-
ing all weights of patients serving as donors for Group I (data
not shown) . Donor weights exceeded recipient weights by an
average of 13% and 31% for Groups [
and II, respectively .
Although donor weights were larger in both groups, the
differences were not statistically significant between groups
(p > 0
.25) . Additionally, intragroup comparisons of survival
with respect to donor/recipient weight ratios among Group I
patients demonstrated no significant differences (the one
patient who died early [Patient 61 had the greatest donor/
o Na./Gender
Diagnosis
Age at
Tx
(yo
PAP
(mean mm Hg)
PAWP
(mm Hg)
PVRI
(unit_')
PVRI
(after vasodilator
infusion, units me)
I/M 0CM 20 37 2- 6 3
21ht DCM 10 52
4
9.7 2 .4
31F DCM 7 52 28 12 8
41F DCM 5 28 1 i 6 -
51M DCM 13
41 24 9
.3 1 .9
61M DCM 15 50 21
8
6
7/F DCM 9 33 16 7 3
BIM DCM 17 74 35 76 8
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Tank 2 . Pretransplantation Diagnoses and Hemodynamic Data for Group II
CCHD = corapkx congenital heart disease; HCM = hypenrophic candiomyopathy : other abbreviations as in
Table 1 .
recipient weight ratio of 1 .8 :1 ; mean 1 .2 :1). Mean perioper- Finally, early postoperative arrhythmias were identified in
alive length of intensive care unit stay was 11 .5 days in 90% of Group I patients and 42% of Group 11 patients (p <
Group I and 15 .1 days in Group ii (p = 0.20), whereas
0 .05)
. lschemic times were 215 t 33 .5 min in Group I
infection rates were 38% for both groups (p > 0.80), neither patients and 225 5: 12 .8 min in Group 11 patients (p = 0.80).
of which represented a statistically significant difference
.
A correlation between arrhythmia and ischemic time did not
Pre-vaaodilator post vasodilator
rime
let post
traasplaola6oa wth
VIM recent Math
Flgwe 1. Change in pretransptan-
tation pulmonary vascular resis-
tance index (PVRI) with vaso-
dilator infusions during cardiac
catheterization. Dashed curve de-
lineates the patient who did not
undergo a pretransplantation va-
sodilator infusion protocol . List
graphs are extended for each pa-
tient (excluding one patient who
died early) to include first post-
transplantation catheterization
(cash) pulmonary vascular resis-
tance index value as well as the
most recent pulmonary vascular
resistance index value (follow-up
periods vary from 0.3 to 6.5
Years).
Pt No ./Gender Diagnosis
Age at Tx
(yr)
PAP
(mean an. Hg)
PAWP
(mm Hg)
PVRI
(units-62)
I/M DCM 1 26 I8
2
.4
2/H CCHD 16
14
12 2
31M I7CM 2
16 - 0.7
4/F CCHD II - - -
TM CCHD 0 .8
10 4 2
6/F CCHD
1
38 12 21
7/F CCHD 2 14 8 3
BIM DCM 12 17 15 3
91F DCM II 25 17 3.6
t0/M CCHD 5 14 13 0.2
IIIM CCHD I - - -
1N DCM 4 22 20 3
13/F DCM 17 12 10 3
I4/IF DCM 9 47 38 4.1
151M CCHD 2 12 II 0 .2
16H
DCM
4 - - -
17/F NCM 11 22 14 3 .3
IS/F NCM
11
14 10 2 .3
191M DCM 8
31
28 1 .5
20/F
HCM 6 27
20 1 .7
211M DCM
10
ID 6 0.6
271M IJCM 4 16 11 3
23/F DCM II - - -
24/M DCM 13 32 32 -
251M DCM 14 16 6 2.6
267H DCM 16 - - -
271F DCM 13 38 31 1 .1
28/F DCM II 36 30 42
2911' DCM D.8 22 15 1.1
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Figure 2. Actuarial survival curve for Group I from the date of
transplantation through a maximal follow-up period of 6 .5 years.
The greatest attrition is seen during the first year after transplanta-
lion, with a zero slope curve from I year after transplantation
through the remainder of the follow-up period . The confidence limits
for this curve are wide because of the small patient numbers .
reach statistical significance with the current number of
patients and data available for analysis .
Postoperative data . Through an average follow up period
of 2.3 years (range 0.3 to 8.5). overall mortality rates were
25% for Group I (one early death (right ventricular failure[,
one late death [rejection/noncompliance]) and 21% for
Group Il (one early death [graft failure], five late deaths
[infection]) (p > 0.80) . Actuarial survival curves for both
groups are shown in Figures 2 and 3 . Pulmonary vascular
resistance indexes were serially assessed at the time of each
posttransplantation catheterization and surveillance endo-
myocardial biopsy . Timing of the first biopsy was slightly
variable but was typica!!y done -10 days after transplanta-
tion . Among Group I patients, pulmonary vascular resis-
tance index decreased from 11 .5 ± 3 .5 units-m2 preopera-
lively to 3 .3 ± 1.2 units-m 2 by the first posttransplantation
biopsy (p < 0.03), which was not statistically different from
the pulmonary vascular resistance index achieved during
vasodilator infusions preoperatively . Subsequent catheter-
ization demonstrated no significant changes in pulmonary
vascular resistance index throughout the follow-up period .
Discussion
Previous studies
. Elevated pulmonary vascular resistance
continues to be a relative contraindication to cardiac trans-
plantation in most centers (1-8). Although there is no
universally accepted value above which transplantation is
absolutely contraindicated, many centers cite a pulmonary
vascular resistance between 6 and 8 Wood units as the upper
limit of acceptability (4,9) . Others suggest that the degree to
which pulmonary vascular resistance decrease during pre-
operative vasodilator agent infusions predicts outcome more
iaausvLaur r- - veg6u'S -1
vu~MC+-F
. xvvEVrE+s
.e..
I
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Figure 3 .
Actuarial survival curve for Group II patients from the
date of transplantation through g
t
years after transplantation . The
greatest patient attrition rate occurs during the first year after
transplantation and subsequently maintains a zero slope distribution
(similar to the Group I survival curve) .
reliably than does the absolute pulmonary vascular resis-
tance (9,10). Much of the data on which these conclusions
are based reflect transplant experience in adult recipients
because there have been few studies examining children
only . One such pediatric study performed by Addonizio et
al . (4) correlated outcomes of pediatric patients with variable
pulmonary vascular resistances and resistance indexes (4) .
Their resets suggested that pulmonary vascular resistance
indexed to body size, which can vary significantly among
pediatric patients, was a better representation of flow imped-
ance throughout the total cross-sectional surface of the pulmo-
nary vascular bed and was, therefore, a supetior measurement
to assess pulmonary vascular resistance and predict outcome .
Pulmonary vascular resistance index >6
units-m2
was associ-
ated with poor survival because of high donor right ventricular
afterload and subsequent ventricular failure . Additionally, they
conth med data previously described in adult transplant recip-
ients that responsiveness of the pulmonary vasculature to
preoperative vasodilators could be a useful prognostic indica-
tor for survival after transplantation .
Present study. Our findings, again obtained solely in
pediatric transplant recipients, support the conclusion that it
is the reactivity of the pulmonary vascular bed, not the
absolute measures of pulmonary vascula" resistance, that
correlated with outcome . If absolute pulmonary vascular
resistance was the sole criteria or which transplantation was
based, six of the eight Group I patients would have been
considered poor candidates and denied transplantation
. Three
of the eight Group I patients were denied transplantation on
previous evaluations at other transplantation centers and were
listed at our center after preoperative vasodilator infusions
demonstrated significant decreases in pulmonary vascular
resistance index, thereby suggesting reversible pulmonary
hypertension and favorable posttransplantation prognosis .
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To maximize allograft function after implantation, patients
with high pulmonary vascular resistance index who had
responded to vasodilator agent therapy during catheteriza-
tion were begun on prostaglandin E 1 infusions preopera-
tively and continued for several postoperative days because
prostaglandin E, administration has been shown to improve
survival in several studies in adult recipients (11,12) . It is
possible that the use of prostaglandin E 1 reduced the dele-
terious effects of elevated pulmonary vascular resistance
postoperatively and resulted in duration of intensive care
unit stays that were similar in both patient groups . Addition-
ally, invasive monitoring lines, chest tubes and catheters
could be expediently removed, minimizing postoperative
infections that resulted in similar intergroup infection rates.
These results suggest that the selection of patients with a
reactive pulmonary bed as well as the use of a pulmonary
vasodilator agent, prostaglandin E l , to maintain lowered
pulmonary vascular resistance perioperatively resulted in
similar survival rates between Groups I and 11 (Fig . 2 and 3).
However, these data are based on a relatively small number
of Group I patients, and there were no patients in this group
who did not receive perioperative vasodilator therapy to
serve as controls for statistical comparisons .
Among Group I patients, seven of the eight children
received orthotopic transplants, and I required heterotopic
transplantation (pulmonary vascular resistance index de-
creased from 36 to 8 units•m2 during preoperative catheter-
ization). Six of the eight patients are alive and doing well .
Only ore death in this group was secondary to acute
postoperative right ventricular failure in an orthotopic recip-
ient, whose baseline pulmonary vascular resistance index
was 8 units-m' . This patient's postvasodilator pulmonary
vascular resistance index was 6 units-ml, demonstrating
minimal reactivity of the pulmonary vascular bed . The other
death was due to noncompliance and late rejection . In an
effort to ensure adequate donor right ventricular function
after transplantation in patients with an elevated pulmonary
vascular resistance index, many centers promote the use of
oversized donors (high donor/recipient weight ratios) with
correspondingly higher donor right ventricular muscle
masses and short ischemic times (restricted donor locales)
(1-3,9). The present study demonstrated no significant dif-
ference in donor/recipient weight ratios when patient groups
were compared and no significant difference in mortality
rates. Allograll ischemic times were not significantly differ-
ent between those children with a high pulmonary vascular
resistance index (215 min) compared with recipients with a
normal pulmonay vascular resistance index (225 min) . Al-
though the number of patients in Group I is relatively small,
the data suggest that donors for patients with a high pulmo-
nary vascular resistance index may only need to be -10%
larger than the recipient, which may ultimately expand the
donor pool for this patient population
. Similarly, both pa-
tient groups tolerated equivalent ischemic times, suggesting
that up to 3
.5 h of ischemia will be tolerated in patients with
reactive pulmonary beds .
JACC Vel . 23. No. 7
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Arrhythmias were more common in patients with an
elevated pulmonary vascular resistance index compared
with those with a normal pulmonary resistance index . A
spectrum of arrhythmias were seen and included hemody-
namicatly insignificant rhythms, including ventricular bigem-
iny and short runs of nonsustained ventricular tachycardia
to life-threatening arrhythmias, such as atrial ectopic tachy-
cardia with rapid ventricular response and ventricular
tachycardia/ventricular fibrillation . Only arrhythmias result-
ing in hemodynamic compromise were treated
. This study
evaluated the possibility that ischemic times may more
reliably correlate with the occurrence of postoperative ar-
rhythmias and demonstrated no statistical correlation . One
may hypothesize that high right ventricular afterload cou-
pled with supranormal ventricular wall stress may potentiate
the occurrence or severity, or both, of postoperative ar-
rhythmias in a recently ischemic myocardium. Additional
patients and further data analysis will be necessary before
this issue can be fully resolved.
Natural history of elevated pahaaaaey resistance after
lrarplamadon. In separate studies by Bourge et al. (5),
Villanueva et al. (13) and Bhalia et al. (14), the time course
and extent to which pulmonary hypertension resolved after
transplantation were examined . Their data were primarily
based on adult patient observations. They concluded that
pulmonary vascular resistance (not pulmonary vascular re-
sistance index) significantly decreased shortly after trans-
plantation and remained so throughout the reported
follow-up period. Their findings were based on data
from patients with a relatively low preoperative resistance
(3 to 6 Wood units) compared with more recent criteria for
elevated pulmonary vascular resistance (>6 to 8 Wood units)
and limited follow-up (m I year) in two of the three studies
(13,14) . Unlike them studies, data reported here were ob-
tained solely in children with an average preoperative pul-
monary vascular resistance index of I I to 12 units-m 2 who
were subsequently followed up for an average of 2.3 years
(range 0.3 to 6.5), thereby documenting the time course over
which pulmonary hypertension resolves in pediatric pa-
tients. Pulmonary vascular resistance index decreased to
values obtained during preoperative vasodilator agent infu-
sions or lower by the first postransplantation catheterization
and surveillance endomyocardial biopsy (-7 to 10 days after
transplantation) . Comparisons of the initial postoperative
pulmonary vascular resistance index with the most recent
measurement revealed no significant change through the
follow-up period. The pulmonary vascular resistance index
in all but one patient decreased in the normal range (I to
3 units-m2 )
; the pulmonary vascular resistance index of the
remaining patient, the heterotopic transplant recipient, de-
creased to -6 units-m2. It is likely that this significant
pulmonary vascular resistance index decrease in the major-
ity of Group I patients reflected significantly improved donor
kit ventricular function, decreasing left atrial pressure,
enhanced forward pulmonary flow and decreased pulmonary
vascular backpressure . The heterotopic transplant recipient
JACC Vol . 23, No . 7
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most likely had an element of arteriolar muscular hypertro-
phy and "fixed" pulmonary hypertension unresolved with
improved ventricular function after transplantation . These
results are somewhat different froln studies in adults where,
in general, a variable degree of "fixed" pulmonary hyper-
tension persists (5,14) . This may reflect differences in prolif-
eration of vascular smooth muscle as a function of the
duration of pulmonary circuit exposure to high pressures in
adults compared with children . However, histologic speci-
mens were not obtained for analysis and validation of this
hypothesis. Future investigations to delineate the potential
intrinsic pathophysiologic differences between pediatric and
adult pulmonary vascular smooth muscle growth and regu-
lation may be useful .
Clinical implications. These data suggest that donor sizes
not >10% to 13% larger than the recipient with ischemic
times of up to 3 .5 h may not significantly affect posttrans-
plantation survival in patients with an elevated pulmonary
vascular resistance index. This may in turn provide a larger
pool from which donors could be selected if further studies
substantiate these findings. Previously unreported, this
study also documents that patients with an elevated pulmn-
nary vascular resistance index are more likely to develop
early postoperative arrhythmias compared with patients
with a normal pulmonary vascular resistance index ; how-
ever, most of these rhythm disturbances were self-limited
and benign, not requiring treatment . Finally, these data
suggest that reactivity
of
the pulmonary vasculature may he
an important determinant
of
transplantation suitability and
may be more useful than the absolute pretransplantation
pulmonary vascular resistance index in an individual patient.
We appreciate the time and assistance offered by O. unen Smith. PhD, who
was imuunlental in the statistical analysis and preparation of the manuscript .
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